[Reflux esophagitis--a community-wide increase in incidence]

Area of Science:

• Gastroenterology
• Digestive Health
• Esophageal Disorders

Background:

• Gastroesophageal reflux disease (GERD) is a prevalent chronic condition with increasing incidence globally.
• GERD manifests with diverse symptoms, including heartburn, extraesophageal symptoms, or can be asymptomatic.
• Pathologic gastroesophageal reflux is often caused by upper GI motility disorders, particularly impaired lower esophageal sphincter (LES) function.

Purpose of the Study:

• To review the current understanding of GERD, its causes, clinical presentations, and management.
• To discuss the evolving classifications for reflux esophagitis and the role of H. pylori infection.
• To highlight the risks of GERD complications and the established and emerging treatment options.

Main Methods:

• Literature review of GERD epidemiology, pathophysiology, clinical features, and treatment modalities.
• Discussion of diagnostic classifications and etiological factors, including motility disorders and H. pylori.
• Analysis of therapeutic strategies, focusing on proton pump inhibitors and emerging endoscopic interventions.

Main Results:

• GERD is characterized by impaired LES function leading to pathologic reflux.
• The Los Angeles classification is proposed for assessing erosive esophagitis, potentially replacing the Savary Miller system.
• Barrett esophagus and adenocarcinoma are significant long-term risks associated with GERD.

Conclusions:

• Proton pump inhibitors (PPIs) are the cornerstone of GERD management for healing, long-term therapy, and prophylaxis.
• The role of H. pylori in GERD pathogenesis remains under investigation.
• New endoscopic therapies for GERD require further evaluation in controlled studies before widespread adoption.